MX9703188A - Acidos nucleicos de aminoacido. - Google Patents

Acidos nucleicos de aminoacido.

Info

Publication number
MX9703188A
MX9703188A MX9703188A MX9703188A MX9703188A MX 9703188 A MX9703188 A MX 9703188A MX 9703188 A MX9703188 A MX 9703188A MX 9703188 A MX9703188 A MX 9703188A MX 9703188 A MX9703188 A MX 9703188A
Authority
MX
Mexico
Prior art keywords
compounds
subject
analogs
another aspect
nucleic acid
Prior art date
Application number
MX9703188A
Other languages
English (en)
Inventor
Kandasamy Ramasamy
Guangyi Wang
Wilfried Seifert
Original Assignee
Icn Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Phamaceuticals Inc filed Critical Icn Phamaceuticals Inc
Publication of MX9703188A publication Critical patent/MX9703188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion proporciona varios análogos de oligonucleotido nuevos, que tienen una o más propiedades que hacen a los compuestos objeto superiores a los oligonucleotidos convencionales para utilizarse en procedimientos que emplean oligonucleotidos. Los compuestos de la invencion son análogos de oligonucleotido en los cuales el anillo furanosa de un ácido nucleico que se presenta en forma natural es reemplazado con un aminoácido o un residuo aminoalcohol modificado. Algunas modalidades de los compuestos de la invencion son particularmente utiles para el control antisentido de la expresion del gen. Los compuestos de la invencion también pueden ser utilizados como sondas o como iniciadores de hibridacion del ácido nucleico. Otro aspecto de la invencion es el proporcionar precursores monoméricos de los análogos oligonucleotidos de la invencion. Estos precursores monomeros pueden ser utilizados para sintetizar los análogos del polinucleotido objeto. Otro aspecto de la invencion es el de proporcionar formulaciones de los análogos del polinucleotido objeto que son diseñadas para el tratamiento o prevencion de enfermedades. Aun otro aspecto de la invencion es del proporcionar métodos para tratar o evitar enfermedades, particularmente infecciones virales y desordenes del crecimiento celular. Los métodos del tratamiento de la enfermedad objeto comprenden la etapa de administrar una cantidad efectiva de los análogos del polinucleotido objeto para utilizarse como inhibidores antisentido.
MX9703188A 1994-11-02 1995-11-02 Acidos nucleicos de aminoacido. MX9703188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33389594A 1994-11-02 1994-11-02
PCT/US1995/014599 WO1996014330A1 (en) 1994-11-02 1995-11-02 Amino acid nucleic acids

Publications (1)

Publication Number Publication Date
MX9703188A true MX9703188A (es) 1997-12-31

Family

ID=23304698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703188A MX9703188A (es) 1994-11-02 1995-11-02 Acidos nucleicos de aminoacido.

Country Status (13)

Country Link
EP (1) EP0789707A4 (es)
JP (1) JPH10508312A (es)
KR (1) KR100393336B1 (es)
CN (1) CN1171112A (es)
AU (1) AU693622B2 (es)
CA (1) CA2202274A1 (es)
HU (1) HU218086B (es)
MX (1) MX9703188A (es)
PL (1) PL185852B1 (es)
RU (1) RU2154638C2 (es)
SI (1) SI9520112A (es)
UA (1) UA48150C2 (es)
WO (1) WO1996014330A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840879A (en) * 1996-12-06 1998-11-24 Wang; Edge R. Reagents and solid supports for improved synthesis and labeling of polynucleotides
IL158316A0 (en) * 2001-04-10 2004-05-12 Univ Leland Stanford Junior Therapeutic and diagnostic uses of antibody specificity profiles
DK2207779T3 (da) * 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
CN103237780B (zh) * 2010-11-30 2015-03-04 独立行政法人科学技术振兴机构 核苷类似物或其盐、寡核苷酸类似物、基因表达抑制剂和用于检测基因的核酸探针
RU2460721C1 (ru) * 2011-02-25 2012-09-10 Учреждение Российской академии наук Институт химической биологии и фундаментальной медицины Сибирского отделения РАН (ИХБФМ СО РАН) Способ получения амидофосфитного мономера ахиральной ненуклеотидной вставки для модификации олигонуклеотидов
DE102014007158A1 (de) * 2014-05-16 2015-11-19 Ugichem Gmbh Neue Peptid-Nukleinsäuren-Monomere und -Oligomere
MX2019014415A (es) 2017-06-16 2020-02-05 Eisai R&D Man Co Ltd Compuesto monomerico de acido nucleico modificado y analogo de acido oligonucleico.
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216860B1 (en) * 1985-03-15 1992-10-28 SUMMERTON, James Stereoregular polynucleotide-binding polymers
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf

Also Published As

Publication number Publication date
PL320084A1 (en) 1997-09-15
CN1171112A (zh) 1998-01-21
KR970707144A (ko) 1997-12-01
JPH10508312A (ja) 1998-08-18
EP0789707A4 (en) 1999-02-24
UA48150C2 (uk) 2002-08-15
EP0789707A1 (en) 1997-08-20
AU693622B2 (en) 1998-07-02
HUT77435A (hu) 1998-04-28
AU4234196A (en) 1996-05-31
WO1996014330A1 (en) 1996-05-17
KR100393336B1 (ko) 2003-12-24
SI9520112A (sl) 1998-08-31
PL185852B1 (pl) 2003-08-29
CA2202274A1 (en) 1996-05-17
RU2154638C2 (ru) 2000-08-20
HU218086B (hu) 2000-05-28

Similar Documents

Publication Publication Date Title
JP4293636B2 (ja) 糖修飾ギャップ付オリゴヌクレオチド
DE10080167B4 (de) Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE69732911T2 (de) Oligoribonukleotide und ribonukleasen zur spaltung von rns
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
AU1647095A (en) Therapeutic ribozyme compositions
CA2229811A1 (en) Inverted chimeric and hybrid oligonucleotides
WO1999057320B1 (en) Antisense modulation of cd40 expression
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
GB2273932A (en) Stable oligonucleotides
Bailly et al. The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA.
MX9703188A (es) Acidos nucleicos de aminoacido.
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
CA2070664A1 (en) Antisense oligonucleotide inhibition of papillomavirus
ATE186464T1 (de) Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur''
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
US5856099A (en) Antisense compositions and methods for modulating type I interleukin-1 receptor expression
CA2342770A1 (en) Ly6h gene
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
JP2007104971A (ja) ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド
HUP0101961A2 (hu) Az FSH-béta-gén módosítása homológ rekombinációval
DE69430740D1 (de) ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN
US9932585B2 (en) Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
HUP0100044A1 (hu) A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok
WO2022144439A3 (en) Oligonucleotides reducing the amount of cd73 mrna and cd73 protein expression

Legal Events

Date Code Title Description
FA Abandonment or withdrawal